Subscribe To

Price Alert Latest News Economic Calendar News

XFOR / X4 Pharmaceuticals to Present at March Investor Conferences

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will participate in a panel at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 and in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Pharmaceuticals

Present

March

Investor

Conferences

Stock

XFOR

Posted: Mar 3 2022, 08:00

Author Name: GlobeNewsWire

XFOR News

By GlobeNewsWire
August 2, 2023

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule

By Seeking Alpha
May 6, 2023

X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors D

By GlobeNewsWire
April 26, 2023

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule

By Proactive Investors
April 12, 2023

X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study

X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 tri

By Seeking Alpha
April 12, 2023

X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match

Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market

By GlobeNewsWire
March 7, 2023

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecul

By Zacks Investment Research
January 31, 2023

What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d

By PennyStocks
December 21, 2022

Penny Stocks To Buy: 6 Insider Picks Before 2023

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.